ARTICLE | Clinical News
CV787: Began Phase I/II study
October 2, 2000 7:00 AM UTC
Calydon Inc., Sunnyvale, Calif. Product: CV787 Business: Cancer Therapeutic category: Cytotoxic Target: Cells expressing PSA Description: Intravenous second generation engineered virus containing huma...